AAM
MRNA icon

Abeille Asset Management’s Moderna MRNA Stock Holding History

Abeille Asset Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$2.27M Buy
+92,086
New +$15.1M 0.08% 85

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Abeille Asset Management's MRNA Position: Q4 2022 in Review

Abeille Asset Management opened a new position in Moderna (MRNA) in Q4 2022: 92,086 shares worth $2.27M. The stake represents 0.08% of the portfolio and ranks #85 among its holdings.

1,071 funds tracked by Wall St. Rank hold MRNA as of Q4 2022.

  • Abeille Asset Management held 92,086 shares of Moderna worth $2.27M as of Q4 2022.
  • Moderna was a new Abeille Asset Management position in Q4 2022.
  • Moderna made up 0.08% of Abeille Asset Management's portfolio in Q4 2022, its #85 holding.
  • 1,071 funds tracked by Wall St. Rank held Moderna as of Q4 2022.

Based on Abeille Asset Management's 13F filing for Q4 2022, filed 20 Jan 2023.